Menu

Filtros : "KALLAS, ESPER GEORGES" "FM" "Lancet hiv" Removido: "LIMA, RAÚL GONZÁLEZ" Limpar

Filtros

Limitar por data

  • 1

1 - 2 (2 registros)

  • Artigo de periodico

    Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study (2022)

    Netto, Lucas C; Ibrahim, Karim Y; Picone, Camila M; Alves, Ana Paula P. S; Aniceto, Eliane V; Santiago, Mariana R; Parmejani, Patricia S. S; Bonfa, Eloisa Silva Dutra de Oliveira ; Kallas, Esper Georges ; Silva, Vivian Helena Iida Avelino da

    Fonte: Lancet hiv. Unidade: FM

    Assuntos: HIV, COVID-19, VACINAS VIRAIS

    Acesso à fonteAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      NETTO, Lucas C et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet hiv, v. 9, n. 5, p. E323-E331, 2022Tradução . . Disponível em: https://doi.org/10.1016/S2352-3018(22)00033-9. Acesso em: 27 jul. 2024.

    • APA

      Netto, L. C., Ibrahim, K. Y., Picone, C. M., Alves, A. P. P. S., Aniceto, E. V., Santiago, M. R., et al. (2022). Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet hiv, 9( 5), E323-E331. doi:10.1016/S2352-3018(22)00033-9

    • NLM

      Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Bonfa ESD de O, Kallas EG, Silva VHIA da. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study [Internet]. Lancet hiv. 2022 ; 9( 5): E323-E331.[citado 2024 jul. 27 ] Available from: https://doi.org/10.1016/S2352-3018(22)00033-9

    • Vancouver

      Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Bonfa ESD de O, Kallas EG, Silva VHIA da. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study [Internet]. Lancet hiv. 2022 ; 9( 5): E323-E331.[citado 2024 jul. 27 ] Available from: https://doi.org/10.1016/S2352-3018(22)00033-9

  • Artigo de periodico

    Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study (2018)

    Grinsztejn, Beatriz; Kallas, Esper G.

    Fonte: Lancet hiv. Unidade: FM

    Assuntos: HIV, INFECÇÕES OPORTUNISTAS, FATORES DE RISCO, HOMENS

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      GRINSZTEJN, Beatriz e KALLAS, Esper G. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet hiv, v. 5, n. 3, p. E136-E145, 2018Tradução . . Disponível em: https://doi.org/10.1016/S2352-3018(18)30008-0. Acesso em: 27 jul. 2024.

    • APA

      Grinsztejn, B., & Kallas, E. G. (2018). Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet hiv, 5( 3), E136-E145. doi:10.1016/S2352-3018(18)30008-0

    • NLM

      Grinsztejn B, Kallas EG. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study [Internet]. Lancet hiv. 2018 ; 5( 3): E136-E145.[citado 2024 jul. 27 ] Available from: https://doi.org/10.1016/S2352-3018(18)30008-0

    • Vancouver

      Grinsztejn B, Kallas EG. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study [Internet]. Lancet hiv. 2018 ; 5( 3): E136-E145.[citado 2024 jul. 27 ] Available from: https://doi.org/10.1016/S2352-3018(18)30008-0
  • 1

1 - 2 (2 registros)

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo     2012 - 2024